 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2010
- 2009
- 2008
- 2007
- [2006]
- 2005
- 2004
- 2003
- 2002
(click to view the full text)
|
December 15, 2006
Æterna Zentaris Shareholders Approve Reduction in Stated Capital and Distribution of Remaining Shares of Atrium Biotechnologies Inc. |
December 11, 2006
Æterna Zentaris Announces Positive Interim Phase 2 Data on Perifosine (KRX-0401) in Patients with Relapsed and Refractory Multiple Myeloma |
December 11, 2006
Æterna Zentaris Participating on Oncology Panel at Upcoming RBC Capital Markets Healthcare Conference in New York |
December 7, 2006
Æterna Zentaris Announces Poster Presentations Highlighting Clinical and Preclinical Activity of Perifosine (KRX-0401) at the American Society of Hematology 48th Annual Meeting |
November 29, 2006
Æterna Zentaris to Initiate Phase 3 Program with Cetrorelix
in BPH |
November 27, 2006
Æterna Zentaris Reports Positive Top Line Phase 1 Results for AN-152 in Patients with Gynaecological and Breast Cancers |
November 27, 2006
Æterna Zentaris to Webcast Analyst Meeting in Toronto on November 29, 2006 |
November 13, 2006
Æterna Zentaris Presents Detailed Positive Phase 2 Data on Ozarelix in Prostate Cancer at SIU Meeting in Cape Town, South Africa |
November 13, 2006
Æterna Zentaris Reports 2006 Third Quarter Results |
November 7, 2006
Æterna Zentaris Will Disclose 2006 Third Quarter Financial and Operating Results on November 13 |
October 31, 2006
Æterna Zentaris to Present at Upcoming CIBC World Markets Conference and Rodman & Renshaw’s 8th Annual Healthcare Conference in New York City as well as Bio Europe in Duesseldorf, Germany |
October 25, 2006
Æterna Zentaris Announces Details of Distribution of its Remaining Shares of Atrium Biotechnologies Inc. |
October 24, 2006
Æterna Zentaris to Present at Upcoming C.E. Unterberg, Towbin Life Sciences Conference and SIG’s Emerging Trend Conference in New York |
October 19, 2006
Æterna Zentaris to Present First In Vivo Data on Ghrelin Antagonists’ Capacity of Selectively Inhibiting Food Intake |
October 18, 2006
Æterna Zentaris Announces Closing of Secondary Offering of Shares of Atrium Biotechnologies Inc. |
October 10, 2006
Æterna Zentaris Announces Delay in Closing of Secondary Offering of Shares of Atrium Biotechnologies Inc. |
October 3, 2006
Æterna Zentaris Announces Positive Phase 2 Results for Ozarelix in Benign Prostatic Hyperplasia |
September 27, 2006
Æterna Zentaris to Present at Upcoming Bio Investor Forum in San Francisco and Bio Contact in Quebec City |
September 21, 2006
Æterna Zentaris Launches Cetrotide® (cetrorelix) in Japan for In Vitro Fertilization |
September 19, 2006
Æterna Zentaris to Sell 3,485,000 Subordinate Voting Shares of Atrium Biotechnologies through Secondary Offering.
• Æterna Zentaris to become a pure play biopharmaceutical company focused on endocrine therapy and oncology.
• Æterna Zentaris intends to complete the spin-off of Atrium by the end of 2006.
This release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or for dissemination in the United States. |
August 11, 2006
Æterna Zentaris Reports 2006 Second Quarter Results |
August 3, 2006
Æterna Zentaris Will Disclose 2006 Second Quarter Financial and Operating Results on August 11 |
August 3, 2006
Æterna Zentaris Enters a License and Collaboration Agreement for Ozarelix with Nippon Kayaku for the Japanese Market |
August 2, 2006
Æterna Zentaris Announces Positive Phase 2 Results for Ozarelix (D 63153) in Hormone-Dependent Inoperable Prostate Cancer |
June 27, 2006
Æterna Zentaris Presented Positive In Vivo Data on ZEN-019, an Oral, LHRH Antagonist Peptidomimetic, at ENDO 2006 in Boston |
June 21, 2006
Æterna Zentaris Receives Green Light from FDA to Move Forward into Phase 3 Program with Cetrorelix in BPH |
June 6, 2006
Æterna Zentaris to Present at Upcoming Pacific Growth Equities Conference in San Francisco and Orion Securities Conference at Mont-Tremblant |
June 5, 2006
Æterna Zentaris Announces Positive Data of Perifosine (KRX-0401) in patients with advanced renal cell carcinoma at ASCO Meeting |
June 5, 2006
Æterna Zentaris Reports Positive Results from ongoing Phase 1 Trial with AN-152 in Patients with Gynaecological and Breast Cancers |
May 26, 2006
Æterna Zentaris to Present at Upcoming Canaccord Adams Life Sciences Mini-Conference in Montreal |
May 16, 2006
Æterna Zentaris to Present at Upcoming Bio Equity Europe 2006 in Frankfurt, Germany |
May 8, 2006
Æterna Zentaris to Present at Upcoming Rodman & Renshaw Conference in Monaco |
May 3, 2006
Æterna Zentaris Announces Research Project with the University of Montreal on its Ghrelin Antagonist Compounds for Obesity at Annual General Meeting |
May 3, 2006
Æterna Zentaris Reports 2006 First Quarter Financial and Operating Results |
April 25, 2006
Æterna Zentaris Will Disclose 2006 First Quarter Financial and Operating Results and Hold Annual General Meeting at the Centre Mont-Royal in Montreal on May 3 |
April 20, 2006
Æterna Zentaris Gains Market Approval for Cetrotide® (cetrorelix) in Japan for In Vitro Fertilization |
April 18, 2006
Æterna Zentaris to Present at Upcoming UBS Global Specialty Pharmaceutical Conference in New York and at
Bio Finance 2006 in Toronto |
April 4, 2006
Æterna Zentaris Discloses Preclinical Results on Various Drug Candidates at the American Association for Cancer Research (AACR) Meeting in Washington |
March 29, 2006
Æterna Zentaris to Present at Upcoming CIBC Biotechnology & Specialty Pharmaceuticals Conference in New York and Bio 2006 in Chicago |
March 28, 2006
Æterna Zentaris to Present Results of Three Preclinical Trials at the American Association for Cancer Research (AACR) Meeting in Washington |
March 1, 2006
Æterna Zentaris Reports 2005 Fourth Quarter and Full-Year Financial and Operating Results |
February 24, 2006
Æterna Zentaris Announces 2005 Fourth Quarter and Full-Year Financial and Operating Results Conference Call and Webcast |
February 22, 2006
Æterna Zentaris to report future financial results in U.S. dollars |
February 17, 2006
Æterna Zentaris Strategic Shareholder, SGF Santé Inc., Exercises Right to Convert a Term Loan into Common Shares |
February 17, 2006
Æterna Zentaris: Update on U.S. NCI sponsored Phase III trial with Neovastat in Non-Small Cell Lung Cancer |
February 15, 2006
Æterna Zentaris Strategic Shareholder, The Solidarity Fund QFL, Exercised its Right to Convert a Term Loan into Common Shares
|
February 7, 2006
Æterna Zentaris to Present at Upcoming Bio CEO & Investor Conference in New York City |
January 30, 2006
Æterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights for Cetrorelix in Benign Prostate Hyperplasia |
January 25, 2006
Æterna Zentaris appoints former Abbott Vice President to its Board of Directors |
 |
 |
